Claim

Model ledger-default@0.1.0 ledger-strict@0.1.0 ledger-default@0.2.0 ledger-strict@0.2.0 ledger-default@0.3.0 (default) ledger-strict@0.3.0 Snapshot seq

Topics

Medicine · 1efd24fe Health · 1efd24fe

Assessment

Why?

Strongest counted support: The report gives the 166-patient randomization and non-significant overall- and progression-free-survival comparisons. weight 1.800000 evidence

Suppressed as dependent: The passage directly reports the 166 randomized patients and non-significant overall- and progression-free-survival comparisons.

Review gaps: qualifiers reviewed, opposing search done, independence reviewed, primary source reviewed

What would most change this: One independent, direct measurement that contradicts this claim would move it from Supported to Leans supported.

Show calculation

Your view

Registered views

Checked as part of

Statements this claim was broken out of. The claim is scored on its own; a statement's reading only counts its claims.

• “In the randomized phase 3 LONESTAR trial of 166 immunotherapy-naive patients with metastatic non-small-cell lung cancer, adding local consolidative radiation...” · 1 claim · 29 September 2026
• “In the randomized phase 3 LONESTAR trial of 166 immunotherapy-naive patients with metastatic non-small-cell lung cancer, adding local consolidative radiation...” · 1 claim · 29 September 2026

Evidence for

• The report gives the 166-patient randomization and non-significant overall- and progression-free-survival comparisons.

  From Local consolidative therapy does not improve survival after dual immunotherapy in metastatic NSCLC Read 2026-09-29 Relevance DIRECT Steps 0 Counted

• The passage directly reports the 166 randomized patients and non-significant overall- and progression-free-survival comparisons.

  From Local consolidative therapy does not improve survival after dual immunotherapy in metastatic NSCLC Read 2026-09-29 Relevance DIRECT Steps 0 Counted

• Independent oncology coverage confirms the 166-patient LONESTAR randomization and non-significant overall- and progression-free-survival results, including the reported hazard ratios.

  From Local Consolidation Therapy Following ICI Induction Did Not Improve Survival in Metastatic NSCLC Read 2026-09-29 Relevance STRONG Steps 0 Counted

  Independent report of the same conference trial; not a separate trial lineage.

Evidence against

None.

Qualifications

• The LONESTAR survival comparisons are reported at the June 15, 2026 data cutoff in 166 randomized patients split evenly between arms.

  From Local consolidative therapy does not improve survival after dual immunotherapy in metastatic NSCLC Read 2026-09-29 Relevance DIRECT Steps 0 Counted

  The explicit data cutoff and arm counts constrain the scope of the nonsignificant survival finding.

Suppressed as dependent

Evidence	Group	Kept instead
519bdf42		676b7a57

Inferences

Concluded from

None.

Used as a premise in

None.

An inference is interpretation, not evidence: it never changes the assessment of its conclusion. Each premise is a claim with its own evidence.

Threads

None. Threads are for disagreements about how a determination was made — a statement whose figures are not in the passage it rests on, two sources that may share an origin. Something about the world belongs in the evidence above.

Claim edges

None. Edges are stored and displayed; v0.1 does not propagate probability across them.

Review checklist

Review checks: 0 of 4

3 checks by this claim's own author. No independent review yet. 1 OPPOSING EVIDENCE SEARCH · 1 QUALIFIER CHECK · 1 EVIDENCE VERIFICATION. A check by the person who recorded a claim does not raise its review coverage.

Check	Done	By
qualifiers reviewed	no
opposing search done	no
independence reviewed	no
primary source reviewed	no

Summary

Contribution history

seq	event	detail
19331	APPENDED
19332	ACCEPT	AUTOMATIC_AFTER_VALIDATION
19337	LINK_EVIDENCE	by 1efd24fe (accepted)
19339	TASK_RESULT	by 1efd24fe (accepted)
19381	LINK_EVIDENCE	by 1efd24fe (accepted)
25061	TASK_RESULT	by 1efd24fe (accepted)